Objective: The objective of this systematic review was to synthesize available research evidence to determine the risk of skin cancer in patients with long-term use of topical corticosteroids (TCS).
Introduction
T opical corticosteroids (TCS) are used to reduce inflammation and are one of the most commonly prescribed medicines in dermatology. They were first used successfully by Sulzberger and Witten in 1952 and their success marked a cornerstone in the history of dermatology. 1 Topical corticosteroids are the mainstay of atopic dermatitis treatment and are used for other skin conditions such as psoriasis, where they are often required for months or years to control the disease and ultimately restore patients' quality of life. Numerous TCS are now available in different preparations, concentrations and potencies; however, when used appropriately TCS efficacy and safety are well established. [2] [3] [4] [5] [6] The beneficial anti-inflammatory effects of TCS are complex, being largely mediated via the cytoplasmic steroid receptor and involving actions on circulating cellular and cytokine mediators of inflammation as well as on the peripheral vasculture. 7 The use of TCS is tempered by consideration of local and less frequently encountered systemic side effects. Known local side effects include skin atrophy, skin striae, contact allergy, rosacea, acne, mild hypopigmentation and hypertrichosis. Rarely, absorption through the skin can cause adrenal suppression, hyperglycaemia and glaucoma. 8 The risk of developing side effects is related to the potency, preparation, frequency and duration of use as well as the age of the patient and the size of the surface area that the TCS are being applied to, or whether the area is vascular or not. In clinical practice, these side effects are uncommon when TCS are used according to their guidance.
There are two types of skin cancers: melanoma and non-melanoma (keratinocyte). Around 97% of skin cancers are non-melanoma (NMSC), comprising mainly of basal cell carcinomas (BCCs) or cutaneous squamous cell carcinomas (cSCCs). The incidence of NMSC is increasing worldwide [9] [10] [11] [12] [13] with an estimated two to three million new cases of NMSC recorded each year.
14 Cutaneous malignant melanoma (CMM) is the most serious form of skin cancer and has been increasing steadily in incidence over the past 30 years. 15 Mortality due to CMM is much higher than that of NMSC. 16 Several observational studies have looked at the relative risk of developing skin cancer due to oral corticosteroid exposure. [17] [18] These studies have provided conflicting results as to whether corticosteroids are associated with an increased risk of skin cancer. Karagas et al. conducted a case-control study on over 800 non-transplant cSSC and BCC patients. 17 The authors found that oral glucocorticoids may increase the risk of non-melanoma skin cancers, whereas Baibergenova et al. found no association between non-melanoma skin cancers and oral corticosteroids in a follow-up study of a chemotherapy trial with 1051 study participants. 18 These studies highlight the clinical equipoise that exists around the impact of oral corticosteroids on the risk of skin cancer.
There have been several epidemiological studies that have explored the risk of cancer specifically amongst atopic dermatitis patients. Hagwstromer et al. conducted a hospital-based study on 15,666 patients with atopic dermatitis in Sweden between 1965 and 1999. 19 The authors reported that men faced a 50% increased risk of non-melanoma skin cancer during the first 10 years of follow-up, but this did not reach statistical significance. The authors did not look at the association between skin cancer and corticosteroid use 19 Wang et al. conducted a review of atopic dermatitis studies published before 2004 and found no consistent associations observed for skin cancers. 20 This review did not look at the effect of TCS use on the risk of skin cancer. At present, it is not known what particular impact TCS have on the risk of skin cancer in the atopic dermatitis population.
With regards the organ transplant population, it is well established that immunosuppression increases the risk of skin malignancy. 21, 22 This occurs when oral corticosteroids are used, although most studies include patients treated with a combination of systemic immunosuppressants including azathioprine and calcineurin inhibitors. 23, 24 Oral corticosteroids are known to have an immunosuppressive effect, and TCS may have a local immunosuppressive effect. 25, 26 It is not known whether TCS may increase the risk of skin cancer through this mechanism.
On the other hand, it is possible that treating skin inflammation with TCS may reduce the risk of skin cancer. Several systematic reviews and meta-analyses have reported the benefits of anti-inflammatory drugs in reducing the risk of cancer, including skin cancers. 27, 28 The management of certain types of inflammatory skin diseases includes the rationale that reducing inflammation reduces the risk of cSCC development in vulval and penile lichen sclerosus as well as hypertrophic lichen planus. It is also known that chronic inflammation is a risk for the SYSTEMATIC REVIEW S. Ratib et al.
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To date, no published systematic review or metaanalysis has been conducted to collate evidence on the effect of long-term TCS use on the risk of skin cancer. The review group examined MEDLINE, Embase, PROSPERO and JBI Database of Systematic Reviews and Implementation Reports and did not find any current or planned reviews on thistopic. Immunosuppression induced by TCS, either local or systemic, may allow these cancers to emerge from reduced immunosurveillance. However, TCS may also reduce the risk of skin cancer in patients where TCS are used to treat inflammatory skin disease. With TCS being one of the most commonly prescribed drugs in the clinical field of dermatology and the increasing incidence of skin cancer, there is a need to review all current evidence about the possible association. The protocol for this systematic review has recently been published. 31 
Review question
The objective of this systematic review was to synthesize available research evidence to determine the risk of skin cancer in patients with long-term use of TCS.
Specifically, the review question is: In people using long-term (more than once a week for one month or longer) TCS, what is the risk of developing skin cancer (clinically or histologically confirmed non-melanoma skin cancer [keratinocyte carcinoma], basal cell carcinoma, cutaneous squamous cell carcinoma or melanoma)?
Inclusion criteria Participants
This review considered studies that included people of all ages, genders and ethnicities. Participants with HIV, transplant participants or participants with genetic diseases (for example, Gorlin-Goltz syndrome) were also considered eligible for the review.
Exposure of interest
This review considered studies that evaluate longterm use of topical corticosteroids. ''Long-term'' was defined as using TCS more than once a week for a month or longer.
Outcome or response
This review considered studies that included the following outcome measures: non-melanoma skin cancer (NMSC) (new nomenclature keratinocyte carcinoma), cutaneous squamous cell carcinoma (cSSC), basal cell carcinoma (BCC) or melanoma skin cancer. These outcomes could be measured by a clinical diagnosis and where available histological confirmation. Pre-cursors such as Bowen's disease were considered secondary outcomes.
Types of studies
This review considered analytical comparative observational studies including prospective and retrospective cohort studies, case-control studies and cross-sectional studies.
Methods

Search strategy
The search strategy aimed to identify both published and unpublished studies. A three-step search strategy was utilized in this review. An initial limited search of MEDLINE and Embase was undertaken followed by an analysis of the text words contained in the title and abstract, and of the index terms used to describe the article. A second search using identified key words and index terms was used to develop a comprehensive search strategy. Studies published in all languages were included.
Information sources
The electronic databases searched included: MED-LINE, Embase and LILACS from inception to November 9, 2017. The search strategy for MED-LINE and LILACS are detailed in Appendix I. The search for unpublished studies included: EThOS at the British Library, Drug Consumption Database, VigiBase and PROTECT ADR Database.
Study selection
Following the search, all identified citations were collated and uploaded in EndNote (Clarivate Analytics, PA, USA) and duplicates removed. Titles and abstracts were then screened by two independent reviewers (SR and EBT) for assessment against the inclusion criteria for the review. The full text of selected citations were retrieved and assessed independently by two reviewers (SR and EBT) in detail against the inclusion criteria. Full text studies that did not meet the inclusion criteria were excluded and SYSTEMATIC REVIEW S. Ratib et al.
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reasons for exclusion were provided. Any disagreements between SR and EBT were resolved by discussion with reviewers JLB and FBH.
Results
Study inclusion
Following a comprehensive and systematic literature search of the identified databases, 2198 results were found). Titles and abstracts were then reviewed against the inclusion criteria and 252 duplicates were concurrently removed. A total of 52 articles were obtained for full review and reasons for exclusion are detailed in Figure 1 . We contacted the authors for one study in order to clarify TCS exposure as their study was the most relevant to our research question. 32 No responses were received from the authors. No studies were found which met the inclusion criteria. Meta-synthesis of findings was therefore not possible.
Data extraction, critical appraisal and data synthesis
As no eligible studies were identified, the process of data extraction, appraisal and synthesis as outlined in the a priori protocol 31 was not required.
Findings of the review
No studies which met the inclusion criteria were found in this systematic review.
Discussion
The overall objective of this quantitative systematic review was to establish if there is an association between long-term TCS use and the risk of skin cancer. We had hoped this review could be used to inform clinicians and patients of the potential adverse effects of this treatment, or conversely to 
Screening Included
Eligibility
IdenƟficaƟon
Records idenƟfied through database searching (n =2198)
AddiƟonal records idenƟfied through other sources (n =0)
Records aŌer duplicates removed (n =252)
Records screened (n =1946)
Records excluded (n =1894)
Full-text arƟcles assessed for eligibility (n =52)
Full-text arƟcles excluded, with reasons (n =52)
Review n=2, conference abstract n=7, case report n=1, oral site n=10, genital site n=18, TCS not exposure n=7, lack of detail about TCS use n=6, skin cancer not outcome n=1
Studies included in quanƟtaƟve synthesis (n =0) minimize unfounded fears of TCS use which is common and often called ''steroid phobia'' in the dermatology community. 33 There were no relevant studies which meant that this objective was not achieved. Several papers were identified which included oral and genital sites; however, these are considered ''special sites'' because disease presentation and risk factors are different to that of other sites of the body and therefore a specific review would be needed in the context of this clinical area. A number of excluded studies merit discussion to place these findings, or lack of, in context in order to inform future research and current clinical evidence based practice.
The study by Landi et al. 32 was the only study identified which had the primary objective of determining whether steroid treatment was associated with skin cancer. However this study did not meet our eligibility criteria as there was no information on frequency and duration of TCS exposure. The authors conducted a case-control study in Italy, from 1994 to 1999, which included patients with cutaneous malignant melanoma (cases) and those without the condition (controls); glucocorticoid (GC) exposure was measured. People with malignant melanoma were less likely to have used GCs (OR ¼ 0.39; 95% CI ¼ 0.20-0.74; n ¼ 362). To overcome confounding by indication, the authors assessed whether the association between GC use and melanoma could be affected by treatment for dermatologic diseases in comparison to treatment for more systemic health problems. The authors also investigated whether the occurrence of melanoma varied by route of administration (oral versus topical) and they took into account ascertainment bias by adjusting for frequency of moles removed in addition to other covariates. The authors concluded that people without melanoma were more likely to have been exposed to glucocorticoid-based therapy than those with melanoma; there was no effect modification by reason for treatment or route of administration. Larger studies would be needed to confirm these findings.
There were three studies which investigated the risk of skin cancer amongst people with dermatological conditions. Ming et al. 62 conducted a casecontrol study in the US between 1998 and 2001 with 1378 NMSC cases and 1533 controls with other dermatologic conditions to explore whether people with NMSC were more likely to have had atopic dermatitis (AD) than those without NMSC. The authors reported that TCS use was a confounder for the association between AD and NMSC. After adjusting for age, sex, ethnicity and TCS use, the odds of AD was 0.78 (96% CI 0.61, 0.98) for those who had NMSC compared to those who did not. The authors also conducted a secondary analysis and reported that the odds of being a TCS user were about 30% less in those with a NMSC as compared with those without a NMSC. However, again, no information on frequency of TCS use was available, a limitation cited by the authors.
Chen et al. 63 investigated the risk of different cancers in people with psoriasis using the Taiwan National Health Insurance Research Database. Skin cancer was associated with psoriasis, especially in younger patients, however the risk did not vary by topical treatment use (all topical treatments were grouped together). Finally, a Dutch cohort study with over 13,000 eczema and psoriasis patients showed the risk of skin cancer was not increased in those taking coal tar compared to those taking dermatocorticosteroids (all steroid treatments were grouped together). 64 
Limitations
The inclusion criteria for this review focused on patients who were exposed to long-term TCS use (more than once a week for a month or longer). There were no studies whose primary objective was to investigate long-term TCS exposure per se, as opposed to any TCS use. No study included information on both duration and frequency of use. We believe that using a specific definition of long-term use based on clinical experience was necessary to maximize the external validity of this review.
Conclusion
We did not find any studies that might help establish if long-term TCS use is associated with skin cancer. Future research using primary care databases may give a better understanding regarding long-term use of TCS and skin cancer.
Recommendations for practice
There was an absence of evidence identified in the review to make clinical recommendations.
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Recommendations for research
There is a significant gap in the evidence base in the area of long-term TCS use and the risk of skin cancer, and therefore future research needs to be conducted to answer this important question. There are several published papers in the area of oral and genital sites, therefore a systematic review in this specific area could be of potential benefit to the dermatology community.
